Efficacy and Safety of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma: a Single-arm, Open-label, Multi-site, Exploratory Phase Ib Study
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2019
Price : $35 *
At a glance
- Drugs Chiauranib (Primary)
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Chipscreen Biosciences
- 22 Jul 2019 Status changed from recruiting to discontinued as the results fell short of expectations.
- 31 Aug 2018 Biomarkers information updated
- 23 May 2017 Planned End Date changed from 1 Mar 2019 to 1 May 2019.